Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
retirement
The top shares of Australia’s best performing super funds
And our equity analysts’ outlook for the stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.70 | 27.80 | 0.31% |
| CAC 40 | 8,122.71 | 23.24 | 0.29% |
| DAX 40 | 23,836.79 | 68.83 | 0.29% |
| Dow JONES (US) | 47,716.42 | 289.30 | 0.61% |
| FTSE 100 | 9,720.51 | 26.58 | 0.27% |
| HKSE | 25,858.89 | 87.04 | -0.34% |
| NASDAQ | 23,365.69 | 151.00 | 0.65% |
| Nikkei 225 | 50,253.91 | 86.81 | 0.17% |
| NZX 50 Index | 13,489.15 | 56.95 | 0.42% |
| S&P 500 | 6,849.09 | 36.48 | 0.54% |
| S&P/ASX 200 | 8,614.10 | 22.30 | 0.26% |
| SSE Composite Index | 3,888.60 | 13.34 | 0.34% |